Dr Kirtane on the Design of the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors
Kedar Kirtane, MD, discusses the design of the phase 1/2 EVEREST-1 trial, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with advanced solid tumors.